{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["UCART123"]],"indication":"blastic plasmacytoid dendritic cell neoplasm","name":"ABC123","nct_id":"NCT03203369","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=abc123-nct03203369. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ABC123","arms":[{"description":"A single intravenous administration of UCART123. Dose escalation in Part 1 will include 3 doses ranging from 6.25 x 10\\^5 cells/kg to 6.25 x 10\\^6 cells/kg and continue until the Recommended Phase 2 Dose (RP2D) is identified.","label":"Part 1: Dose Escalation","type":"EXPERIMENTAL"},{"description":"A single intravenous administration of UCART123 at the RP2D. 2 Cohorts: Patients with Relapsed/Refractory BPDCN and Newly Diagnosed BPDCN.","label":"Part 2: Dose Expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2019-06-27","type":"ACTUAL"},"conditions":["Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)"],"enrollment":{"count":1,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"UCART123","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2019-07-31","lead_sponsor":"Cellectis S.A.","official_title":"Phase 1, Open-label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of a Single Dose of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","overall_status":"TERMINATED","phases":["PHASE1"],"primary_completion_date":{"date":"2019-06-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Incidence, nature, and severity of adverse events and serious adverse events","timeFrame":"Through day 84"}],"references":[],"start_date":{"date":"2017-06-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN","url":"https://clinicaltrials.gov/study/NCT03203369"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/abc123-nct03203369"}